Sino Biopharmaceutical Limited (the Company or Sino Biopharmaceutical) announced that Chia-Tai Tianqing Pharmaceutical Group Co., Ltd. (Chia- Tai Tianqing) entered into an exclusive license and cooperation agreement with Inventisbio Co. Ltd. (Inventisbio), pursuant to which Chia-Tai Tianqing was granted an exclusive license by Inventisbio to develop, register, manufacture and commercialize D-1553 in Mainland China. In addition, based on potential future cooperation in data sharing, Chia-Tai Tianqing will be granted a certain % age of rights outside Mainland China in due course.

D-1553 is a KRAS G12C inhibitor independently developed by Inventisbio, used for the treatment of non-small cell lung cancer (NSCLC), colorectal cancer and other cancers carrying KRAS G12C mutation. It is the first KRAS G12C inhibitor that is independently developed and has entered the clinical trial stage in Mainland China, and international multi-center clinical trials of D-1553 have been carried out in the United States, Australia, China, South Korea, Taiwan, China and other countries and regions. In May 2022, D-1553 received approval from the Center for Drug Evaluation of the National Medical Products Administration of China to conduct a phase II clinical trial as monotherapy for the treatment of KRAS G12C mutation-positive NSCLC.

Currently, D-1553 is undergoing international multi-center clinical studies for monotherapy and combination therapy in the first-line treatment of NSCLC as well as other solid tumors such as colorectal cancer, and is in the phase II clinical trial stage. Oncology is one of the four major therapeutic areas of Sino Biopharmaceutical's innovation and development. After years of intensive cultivation, a number of heavyweight products have been launched, and several innovative drug projects are in the clinical development stage.

The introduction of D-1553 will further enrich Sino Biopharmaceutical's oncology innovative drug pipeline and improve Sino Biopharmaceutical's strategic layout in the oncology field. With its extensive experience in innovative research and development, drug manufacturing and commercialisation, Sino Biopharmaceutical will accelerate the launch of this product to meet the urgent needs of oncology patients.